The Business Times
business-time-50

Lonza in joint venture to develop biotherapeutic products

google-preferred-sourceAdd BT as a preferred source

Ng Ren Jye

Published Wed, Apr 3, 2019 · 09:50 PM

Singapore

SWISS biotech company Lonza has entered into an equal joint venture (JV) with Danish bioscience company Chr Hansen Holding to develop live biotherapeutic products (LBP) for pharma and biotech customers.

The phased investment of about 90 million euros (S$136.6 million) will be shared equally between the partners over three years.

lonza

TRENDING NOW

“I consider myself lucky. I don’t consider myself successful,” says Ng Yih Pyng, the second-generation leader of Tomei Consolidated.

What’s luck got to do with it? Everything, says Malaysian jewellery king Tomei’s chief

Senior Judge Lee Seiu Kin rejects Chander Agarwal’s characterisation of the expenses as loans, pointing to a pattern of lavish spending on Felicia Lee.

Hell hath no fury like a man scorned: CEO’s S$468,000 suit against ex fails after relationship sours

Despite the current sell-off, currency strategists view the ringgit’s slide as temporary.

Singdollar hits 10-month high against ringgit as investors take refuge in traditional safe haven

Canadian Prime Minister Mark Carney speaking at a press conference in Ottawa, on Aug 22, after trade talks with the US collapsed.

Canada’s fight with the US has far bigger stakes than trade

Latest T-bills Treasury Bills Results & Interest NewsLatest SSB Singapore Savings Bonds NewsLatest COE Certificate of Entitlement News
Latest Johor-Singapore SEZ NewsLatest BTO Build To Order & Sales of Balance NewsLatest STI Straits Times Index NewsLatest SGX Dividends, Share Price NewsLatest Bonds Market NewsLatest Singapore Stocks To Buy NewsLatest Singapore Economy News
View More